Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study.

Transl Lung Cancer Res · 2024 · PMC11304149 · PMID 39118877

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

a notable trendP=0.07so close (0.05 < p ≤ 0.1)

In the prospective controlled STEREOBRAIN trial, which compared patients receiving SRS for four to ten metastases with a matched historic WBRT cohort, a notable trend towards overall benefit was observed for SRS, demonstrating a median survival of 10.4 months compared to 7.1 months in the historic cohort (P=0.07), approaching statistical significance ( 9 ).

also in 902 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.